The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schjetne, K. W.
Right arrow Articles by Bogen, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schjetne, K. W.
Right arrow Articles by Bogen, B.
The Journal of Immunology, 2003, 171: 32-36.
Copyright © 2003 by The American Association of Immunologists


CUTTING EDGE

Cutting Edge: Link Between Innate and Adaptive Immunity: Toll-Like Receptor 2 Internalizes Antigen for Presentation to CD4+ T Cells and Could Be an Efficient Vaccine Target1

Karoline W. Schjetne2,*, Keith M. Thompson*, Nadra Nilsen{dagger}, Trude H. Flo{dagger}, Burkhard Fleckenstein*, Jens-Gustav Iversen{ddagger}, Terje Espevik{dagger} and Bjarne Bogen*

* Institute of Immunology, University of Oslo, Rikshospitalet, Oslo, Norway; {dagger} Institute for Cancer Research and Molecular Biology, Norwegian University of Science and Technology, Olav Kyrres gt 3, Trondheim, Norway; and {ddagger} Institute of Physiology, University of Oslo, Oslo, Norway

An ideal vaccine for induction of CD4+ T cell responses should induce local inflammation, maturation of APC, and peptide loading of MHC class II molecules. Ligation of Toll-like receptor (TLR) 2 provides the first two of these three criteria. We have studied whether targeting of TLR2 results in loading of MHC class II molecules and enhancement of CD4+ T cell responses. To dissociate MHC class II presentation from APC maturation, we have used an antagonistic, mouse anti-human TLR2 mAb (TL2.1) as ligand and measured proliferation of a mouse C{kappa}-specific human CD4+ T cell clone. TL2.1 mAb was 100-1000 times more efficiently presented by APC compared with isotype-matched control mAb. Moreover, TL2.1 mAb was internalized into endosomes and processed by the conventional MHC class II pathway. This novel function of TLR2 represents a link between innate and adaptive immunity and indicates that TLR2 could be a promising target for vaccines.




This article has been cited by other articles:


Home page
J. Immunol.Home page
M. Flobakk, I. B. Rasmussen, E. Lunde, T. Frigstad, G. Berntzen, T. E. Michaelsen, B. Bogen, and I. Sandlie
Processing of an Antigenic Sequence from IgG Constant Domains for Presentation by MHC Class II
J. Immunol., November 15, 2008; 181(10): 7062 - 7072.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
N. J. Nilsen, S. Deininger, U. Nonstad, F. Skjeldal, H. Husebye, D. Rodionov, S. von Aulock, T. Hartung, E. Lien, O. Bakke, et al.
Cellular trafficking of lipoteichoic acid and Toll-like receptor 2 in relation to signaling; role of CD14 and CD36
J. Leukoc. Biol., July 1, 2008; 84(1): 280 - 291.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
E. Tagliani, P. Guermonprez, J. Sepulveda, M. Lopez-Bravo, C. Ardavin, S. Amigorena, F. Benvenuti, and O. R. Burrone
Selection of an Antibody Library Identifies a Pathway to Induce Immunity by Targeting CD36 on Steady-State CD8{alpha}+ Dendritic Cells
J. Immunol., March 1, 2008; 180(5): 3201 - 3209.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
Q. Wang, R. M. McLoughlin, B. A. Cobb, M. Charrel-Dennis, K. J. Zaleski, D. Golenbock, A. O. Tzianabos, and D. L. Kasper
A bacterial carbohydrate links innate and adaptive responses through Toll-like receptor 2
J. Exp. Med., December 25, 2006; 203(13): 2853 - 2863.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
Y. F. Lau, G. Deliyannis, W. Zeng, A. Mansell, D. C. Jackson, and L. E. Brown
Lipid-containing mimetics of natural triggers of innate immunity as CTL-inducing influenza vaccines
Int. Immunol., December 1, 2006; 18(12): 1801 - 1813.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
G. Tunheim, K. W. Schjetne, A. B. Fredriksen, I. Sandlie, and B. Bogen
Human CD14 is an efficient target for recombinant immunoglobulin vaccine constructs that deliver T cell epitopes
J. Leukoc. Biol., March 1, 2005; 77(3): 303 - 310.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. U. Saikh, T. L. Kissner, A. Sultana, G. Ruthel, and R. G. Ulrich
Human Monocytes Infected with Yersinia pestis Express Cell Surface TLR9 and Differentiate into Dendritic Cells
J. Immunol., December 15, 2004; 173(12): 7426 - 7434.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Grabiec, G. Meng, S. Fichte, W. Bessler, H. Wagner, and C. J. Kirschning
Human but Not Murine Toll-like Receptor 2 Discriminates between Tri-palmitoylated and Tri-lauroylated Peptides
J. Biol. Chem., November 12, 2004; 279(46): 48004 - 48012.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
D. C. Jackson, Y. F. Lau, T. Le, A. Suhrbier, G. Deliyannis, C. Cheers, C. Smith, W. Zeng, and L. E. Brown
A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses
PNAS, October 26, 2004; 101(43): 15440 - 15445.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. Nilsen, U. Nonstad, N. Khan, C. F. Knetter, S. Akira, A. Sundan, T. Espevik, and E. Lien
Lipopolysaccharide and Double-stranded RNA Up-regulate Toll-like Receptor 2 Independently of Myeloid Differentiation Factor 88
J. Biol. Chem., September 17, 2004; 279(38): 39727 - 39735.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
E. Latz, J. Franko, D. T. Golenbock, and J. R. Schreiber
Haemophilus influenzae Type b-Outer Membrane Protein Complex Glycoconjugate Vaccine Induces Cytokine Production by Engaging Human Toll-Like Receptor 2 (TLR2) and Requires the Presence of TLR2 for Optimal Immunogenicity
J. Immunol., February 15, 2004; 172(4): 2431 - 2438.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
M. B. Drennan, D. Nicolle, V. J. F. Quesniaux, M. Jacobs, N. Allie, J. Mpagi, C. Fremond, H. Wagner, C. Kirschning, and B. Ryffel
Toll-Like Receptor 2-Deficient Mice Succumb to Mycobacterium tuberculosis Infection
Am. J. Pathol., January 1, 2004; 164(1): 49 - 57.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2003 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2003 by The American Association of Immunologists, Inc. All rights reserved.